Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Parkinson Disease ll: Pathophysiology

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...

Parkinson Disease l: Introduction

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...

Parkinson's Disease: Overview

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...

Neural Regulation

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.

Alzheimer Disease ll: Pathophysiology

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Integrated Gait and Pose Analysis Utilizing Computer Vision for Parkinsonian Behavioral Phenotyping in Mice.

bioRxiv : the preprint server for biology·2026

Same author

Detection of phosphorylated α-synuclein in skin - Authors' reply.

The Lancet. Neurology·2026

Same author

Targeted antisense oligonucleotide treatment rescues developmental alterations in spinal muscular atrophy organoids.

Nature communications·2025

Same author

Parkinson's Disease, Second Edition.

Cold Spring Harbor perspectives in medicine·2025

Same author

Rare <i>PANK2</i> variants and pantothenate-kinase-associated neurodegeneration in the Dominican Republic.

Brain communications·2025

Same author

Single-cell transcriptomic landscape of the neuroimmune compartment in amyotrophic lateral sclerosis brain and spinal cord.

Acta neuropathologica·2025

Search research articles

Related Experiment Videos

Inflammation and Parkinson's disease pathogenesis.

Serge Przedborski¹

¹Department of Neurology, Pathology and Cell Biology, Columbia University, New York, New York, USA. SP30@Columbia.edu

Movement Disorders : Official Journal of the Movement Disorder Society

|February 27, 2010

Summary

This summary is machine-generated.

Neuroinflammation, driven by activated glial cells, contributes to Parkinson's disease neurodegeneration. Targeting this inflammation and glial-derived toxins offers a promising neuroprotective treatment strategy.

Related Experiment Videos

Area of Science:

Neuroscience
Immunology
Pathology

Background:

Inflammation is a key neuropathological feature in Parkinson's disease (PD) brains and relevant animal models.
Activated glial cells are the primary drivers of the inflammatory response in PD.
These glial cells produce toxic molecules that exacerbate neurodegeneration.

Purpose of the Study:

To investigate the role of neuroinflammation in Parkinson's disease pathogenesis.
To explore the contribution of glial cells to the neurodegenerative process in PD.
To identify potential therapeutic targets for neuroprotection in Parkinson's disease.

Main Methods:

Analysis of neuropathological features in parkinsonian brains.
Examination of experimental models of Parkinson's disease.
Assessment of glial cell activation and toxic molecule production.

Main Results:

Confirmed inflammation as a significant neuropathological hallmark of Parkinson's disease.
Identified activated glial cells as major contributors to PD-related inflammation.
Demonstrated the production of toxic molecules by glial cells, promoting neurodegeneration.

Conclusions:

Reducing neuroinflammation is a potential therapeutic strategy for Parkinson's disease.
Inhibiting glial-derived toxic molecules may offer neuroprotection.
Targeting glial cell activity presents a promising avenue for Parkinson's disease treatment.